Netherlands-based Cristal Therapeutics has launched a Phase Ib clinical programme to assess its nanomedicine candidate CriPec-docetaxel for the treatment of solid tumours.

CriPec-docetaxel is being developed as a new drug modality to entrap a clinically validated chemotherapy, docetaxel (Taxotere), as therapeutic payload into nanoparticles.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Designed to allow increased tumour accumulation and local release of the drug, the candidate is intended to enhance therapeutic efficacy and overcome challenges such as toxic systemic side-effects associated with existing docetaxel products.

In addition to evaluation of the distribution and uptake of the nanomedicine candidate, Phase Ib programme will determine an optimal frequency and dosing schedule for Phase II clinical efficacy trials.

Cristal Therapeutics CEO and co-founder Dr Joost Holthuis said: “Progressing CriPec-docetaxel to a Phase Ib programme is an important milestone, and highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study.

“This highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study.”

“We look forward to the results of the consolidated Phase I programme.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The preliminary positive data obtained from the open-label, safety and pharmacokinetic Phase Ia trial indicated favourable safety and tolerability of the nanomedicine.

Furthermore, the results revealed that CriPec-docetaxel could be given at therapeutic dose levels.

In addition, the nanomedicine candidate is reported to have shown improved pharmacokinetic profile, when compared with other docetaxel-based drug products such as Taxotere.

The Phase 1b programme is being performed at three clinical sites across the Netherlands and at the University Hospitals Leuven General Medical Oncology department in Belgium.

 

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now